ALLISON HARWOOD: Open Payments
NPI 1285410845 · OSHKOSH, WI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$385 in 16 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $599 · 2025 $385
Food & beverage: $385
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 3 | $79 |
| Neurocrine BioSciences, Inc. | 2 | $49 |
| Sage Therapeutics, LLC | 2 | $41 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $30 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Alkermes, Inc. | 1 | $26 |
| E.R. Squibb & Sons, L.L.C. | 1 | $26 |
| Tris Pharma Inc | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
Products named: REXULTI, INGREZZA, ZURZUVAE, CAPLYTA, Auvelity, ARISTADA, COBENFY, Dyanavel XR.
Industry payments across WI — which companies pay providers there.
